Tardive dyskinesia history

Current tardive dyskinesia History of non-adherence Clozapine, quetiapine Long-acting risperidone Risperidone, olanzapine, ziprasidone... 

In a retrospective study in a psychiatric hospital in Curasao, Netherlands Antilles, 133 Afro-Caribbean inpatients (mean age 52 years), with no organic disorders and a history of current use of neuroleptic drugs for at least 3 months, were assessed for tardive dyskinesia (291). The prevalence was 36%. When the number of interruptions to neuroleptic drug therapy was split into up to two and more than two, the resulting adjusted odds ratio was 3.29 (95% Cl = 1.27, 8.49). Thus, the number of interruptions turned out to be the second risk factor after age. Cumulative dosages of neuroleptic or anticholinergic drugs were not risk factors. 

Tardive dystonia has sometimes been thought to be a subtype of tardive dyskinesia (SED-13, 123). However, some features of this condition are clearly different from those of tardive dyskinesia (SEDA-20, 41). The diagnosis of tardive dystonia should meet the following criteria (a) the presence of chronic dystonia (b) a history of neuroleptic drug treatment preceding (less than 2 months) or... 

Attention deficit hyperactivity disorder (ADHD) may be a susceptibility factor for risperidone-induced tardive dyskinesia and withdrawal dyskinesia. Both conditions have occurred in patients with a past or recent history of attention deficit hyperactivity disorder. 

The length of follow-up was 3-393 (mean 115). weeks 60 developed dyskinesias. The cumulative incidences were 25%, 34%, and 53% after 1, 2, and 3 years respectively of cumulative neuroleptic drug treatment. A greater risk of tardive dyskinesia was associated with a history of electroconvulsive therapy (ECT), higher mean daily and cumulative neuroleptic drug doses, and the presence of extrapyramidal signs early in treatment. 

Caution History of peptic ulcer disease, dementia, psychosis, tardive dyskinesia, profound tremor, cardiac dysrhythmias... 

---